Board of Directors

Science Board Advisors

Portrait

Dr. Dhingra is a medical oncologist and a physician-scientist with a proven track record in academic research, patient care, and drug development. He served as Vice President, Head of the Oncology Disease Biology Leadership Team and Head of Oncology Clinical Development at Hoffmann-La Roche (“Roche”), during which he led numerous drug approvals, including Herceptin®, Tarceva®, and Avastin®. Prior to joining Roche, he worked in the oncology clinical development group at Eli Lilly and Company. Dr. Dhingra has served as a faculty member at The University of Texas M.D. Anderson Cancer Center, Indiana University School of Medicine, and Memorial Sloan Kettering Cancer Center. Dr. Dhingra is currently a member of the Boards of Directors of LAVA Therapeutics, Black Diamond Therapeutics, Inc., Replimune, Inc., Autolus Therapeutics plc, and Median Technologies, and he has previously served on the boards of several successful biotech companies, including Biovex, Micromet, Algeta, YM Biosciences, Epitherapeutics, Advanced Accelerator Applications, Exosome Diagnostics, and, Five Prime Therapeutics. He is a member of the NCI Experimental Therapeutics Panel. Dr. Dhingra founded KAPital Consulting, LLC in 2008, a company dedicated to helping biotechnology, pharmaceutical, and diagnostic companies realize the clinical and commercial advances in oncology. Dr. Dhingra obtained his M.B.B.S. degree from the All India Institute of Medical Sciences in New Delhi, India. He completed his residency in internal medicine at Lincoln Medical and Mental Health Center, New York Medical College and completed his fellowship in hematology and oncology at Emory University School of Medicine.

Portrait

Professor and Director of CCIT (Center for Cancer Immune Therapy at Herlev University Hospital. Mads Hald Andersen has received several honors for his scientific work and is the author of more than 130 papers. MHA has founded and co-founded several spin out companies with a successful sale of Survac in 2006.

Portrait

Professor and Director of CCIT (Center for Cancer Immune Therapy) at Herlev University Hospital. IMS has extensive experience in clinical translation of immune therapies and is an advisor for several large pharma companies. Currently running a phase III trial.

Portrait

Alexander Eggermont, MD, PhD, is currently Professor of Immunotherapy at the University Medical Center Utrecht in the Netherlands, Scientific Director of the Princess Maxima Center for Pediatric Oncology, Utrecht, the Netherlands and Board Member of the Comprehensive Cancer Center Munich between the Technical University Munich and the Ludwig Maximiliaan University, Munich, Germany.

He is the past Directeur Général of the Gustave Roussy Cancer Institute (2010-2019) and Professeur Oncologie «Classe Exceptionelle», at the Université Paris-Saclay (2012-2020). He was head of Department of Oncological Surgery at the Erasmus University of Rotterdam, Netherlands 2003-2017. He also holds the Joseph Maisin Honorary Chair of Oncological Surgery at the Louvain Catholic University (Belgium). He is a Melanoma, Soft tissue sarcoma and Immunotherapy specialist and Fellow of the NIH-NCI Surgery Branch (Chief Steve Rosenberg). During his career, he was o.a. President of the the EORTC (European Organization for Research and Treatment of Cancer) from 2003 to 2006 and President of ECCO (European CanCer Organization) from 2008 to 2010, and President of the of the European Academy of Cancer Sciences (2011-2019).